Cargando…
Anticancer mechanism of breviscapine in non-small cell lung cancer A549 cells acts via ROS-mediated upregulation of IGFBP4
BACKGROUND: The overall 5-year survival rate of non-small cell lung cancer (NSCLC) is less than 15% because of multiple drug resistance to chemotherapy and the limitations of early diagnosis. Thus, safe and effective drugs to treat NSCLC are required. The present study aimed to investigate the effec...
Autores principales: | Wei, Weitian, Wang, Liang, Xu, Liwei, Zeng, Jian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107560/ https://www.ncbi.nlm.nih.gov/pubmed/34012594 http://dx.doi.org/10.21037/jtd-21-551 |
Ejemplares similares
-
Opposing Roles of IGFBP-3 and Heparanase in Regulating A549 Lung Cancer Cell Survival
por: Al Khashali, Hind, et al.
Publicado: (2022) -
Breviscapine ameliorates CCl(4)-induced liver injury in mice through inhibiting inflammatory apoptotic response and ROS generation
por: Liu, Yu, et al.
Publicado: (2018) -
Therapeutic Effects of Breviscapine in Cardiovascular Diseases: A Review
por: Gao, Jialiang, et al.
Publicado: (2017) -
Anticancer Effects of Valproic Acid via Regulation of Epigenetic Mechanisms in Non-small-cell Lung Cancer A549 Cell Line
por: Kalantar, Hadi, et al.
Publicado: (2021) -
Anticancer Properties of Fluorinated Aminophenylhydrazines on A549 Lung Carcinoma Cell Line
por: SAK, Zafer Hasan Ali, et al.
Publicado: (2021)